| Multimodality approach in management of malignant pleural mesothelioma. | |
| | |
MedLine Citation:
|
PMID: 16343925 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Malignant pleural mesothelioma (MPM) is a solid, locally aggressive tumor, which has been closely linked to asbestos exposure. The survival rate without treatment ranges from 4 to 12 months. Response to chemotherapy and radiation is poor, and surgery is the most effective therapy. There are currently 3000 new MPM cases per year in the United States, with the peak incidence in the United States and Europe expected to occur in the year 2020. The prognosis depends on the stage of the tumor at the time of diagnosis, its histological type, lymph node status, and resection margins. While the diagnosis is often delayed, earlier intervention may improve life expectancy. Single-modality therapy has not been effective in changing the natural history of MPM. As a result, multimodality regimens involving surgery with radiation, chemotherapy, or immunotherapy have been initiated. Multiple modality approach has demonstrated favorable outcome, particularly in patients with epithelial histology, negative resection margins and presence of no metastases to extrapleural lymph nodes. Cisplatin and mitomycin have demonstrated modest efficacy in management of distant tumor recurrence. Cisplatin and gemcitabine regimen as well as cisplatin/pemetrexed followed by 54 Gy of adjuvant hemithorax radiation have been reported to improve the outcome. |
| | |
Authors:
|
Siyamek Neragi-Miandoab |
Related Documents
:
|
9270245 - Intrapericardial administration of cisplatin in treatment of metastatic pericardial inv... 21655995 - A multiple-center phase ii study of weekly docetaxel and oxaliplatin as first-line trea... 21843915 - A role for maintenance therapy in managing sarcoma. 15332395 - Efficacious pleurodesis with ok-432 and doxorubicin against malignant pleural effusions. 22473255 - Advancing resuscitation science. 9072585 - Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplat... |
Publication Detail:
|
Type: Journal Article; Review Date: 2005-12-15 |
Journal Detail:
|
Title: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery Volume: 29 ISSN: 1010-7940 ISO Abbreviation: Eur J Cardiothorac Surg Publication Date: 2006 Jan |
Date Detail:
|
Created Date: 2005-12-26 Completed Date: 2006-03-09 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8804069 Medline TA: Eur J Cardiothorac Surg Country: Germany |
Other Details:
|
Languages: eng Pagination: 14-9 Citation Subset: IM |
Affiliation:
|
Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Chicago, Stritch School of Medicine, Maywood, IL, USA. sneragi@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antimetabolites, Antineoplastic
/
therapeutic use Antineoplastic Agents / therapeutic use Cisplatin / therapeutic use Combined Modality Therapy / methods Deoxycytidine / analogs & derivatives, therapeutic use Drug Therapy, Combination Gene Therapy / methods Humans Immunotherapy / methods Mesothelioma / drug therapy, radiotherapy, therapy* Palliative Care / methods Pleural Neoplasms / drug therapy, radiotherapy, therapy* Thoracic Surgical Procedures / mortality Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antimetabolites, Antineoplastic; 0/Antineoplastic Agents; 103882-84-4/gemcitabine; 15663-27-1/Cisplatin; 951-77-9/Deoxycytidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hospital volume: operative morbidity, mortality and survival in thoracotomy for lung cancer. A Spani...
Next Document: Hot flushes in breast cancer patients.